CRO Expands Clinical Capabilities, Accelerating Product Pipeline Development and Commercialization Opportunities
- Company Reports Sequential Revenue Growth of 12% Over Q4 2023 and Strong Gross Margins of 64% -
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Agency has indicated it expects to complete the review by end of May
Enhanced Leadership, Revamped Sales Organization, Drive Improved Sales Efficiency and Customer Retention